Ovarian cancer vaccine - Northwest Biotherapeutics

Drug Profile

Ovarian cancer vaccine - Northwest Biotherapeutics

Alternative Names: Autologous dendritic cell vaccine (DCVax-L) for recurrent ovarian or primary peritoneal cancer - Northwest Biotherapeutics; Autologous dendritic cell vaccine leaded with autologous tumour cell lysate (DCVax-L) - Northwest Biotherapeutics; DCVac-L - Northwest Biotherapeutics; DCVax-L (Ovarian); DCVax-L (Peritoneal); DCVax-Ovarian

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwest Biotherapeutics
  • Developer Northwest Biotherapeutics; University of Pennsylvania Cancer Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ovarian cancer
  • Phase I Peritoneal cancer

Most Recent Events

  • 28 Feb 2017 Phase-I/II development is ongoing in USA (Intradermal)
  • 10 Nov 2014 Phase-I/II clinical trials in Ovarian cancer (Metastatic disease, Recurrent) in USA (Intradermal) prior to November 2014
  • 11 Feb 2013 Phase-I development is completed for metastatic Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top